Roche Holding stock gets FDA approval for Wilserdly breast pill
Published on 11/17/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA approval opens a new oncology opportunity
- Wilserdly received US approval with everolimus for a defined group of patients with advanced breast cancer.
- The evERA study showed a 62 percent reduction in the risk of disease progression or death versus standard endocrine therapy with everolimus.
- The FDA is expected to decide by November 30 on an additional early-stage breast cancer indication.
Roche said on Monday, November 16, that the U.S. Food and Drug Administration approved Wilserdly, also known as giredestrant, in combination with everolimus for a defined group of adults with advanced breast cancer. The approval covers estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic disease detected by an FDA-authorized test, after recurrence following adjuvant endocrine therapy or progression on at least one endocrine-based metastatic regimen. Roche published the announcement in its FDA approval release.
Roche Holding stock traded at 442.48 euros on Lang & Schwarz at 11:10 CET on Tuesday, November 17.
Study results underpin the approval
The decision was supported by the phase III evERA Breast Cancer study. In patients whose ESR1-mutated tumors had progressed after treatment with a CDK4/6 inhibitor, Wilserdly plus everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy plus everolimus. Roche reported a stratified hazard ratio of 0.38, with a 95 percent confidence interval of 0.27 to 0.54 and a p-value below 0.0001.
The company said the combination prolonged progression-free survival in the study population. Roche's release describes Wilserdly as an oral selective estrogen receptor degrader designed to inhibit estrogen-receptor signaling. Combined with everolimus, it targets a second pathway involved in endocrine resistance. The fully oral regimen also avoids injections, according to Roche Chief Medical Officer Levi Garraway.
Next decision could widen the market
Roche is seeking a second U.S. indication for Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The FDA accepted that application for Priority Review and set a Prescription Drug User Fee Act date of November 30, 2026. Approval in that setting would extend the medicine from advanced disease into earlier-stage treatment.
The current approval gives Roche a commercial entry point while its broader development program remains active. The company says its Wilserdly program includes six company-sponsored phase III studies across different treatment settings and lines of therapy. The regulatory outcome and the pending adjuvant decision are therefore key milestones for the group's breast-cancer franchise.
Roche Holding at a glance
- Company: Roche Holding AG
- ISIN: CH1499059983
- Lang & Schwarz quote: 442.48 euros, Tuesday, November 17, 2026, 11:10 CET
- Regulatory event: U.S. FDA approval of Wilserdly on November 16, 2026
The Swiss market backdrop can be followed via the SMI.
